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Awaiting the OSCAR subanalysis
of subjects according to the
presence of proteinuria
To the Editor: We read with great interest the article
describing the OSCAR Study:1 compared with high-dose
angiotensin receptor blocker (ARB) monotherapy, the ARB/
calcium-channel blocker combination conferred a greater
reduction in cardiovascular risk in patients with chronic
kidney disease (CKD), as defined by a glomerular filtration
rate o60ml/min per 1.73m2.
Our study group proposes the following: (1) high sodium
sensitivity originates in impaired renal sodium excretion and
thus causes sodium retention to augment the cardiovascular
burden and (2) the steady-state amount of sodium intake
(UNaV, y-axis) could be represented as a first-order function
of blood pressure (MAP, x-axis): UNaV¼B(MAP-A), where
A and B represent the extrapolated x-intercept and the slope
of the pressure-natriuresis curve, respectively.2 Sodium
sensitivity index (SI) was interpreted as the reciprocal of
the slope (B) and MAP–A as the net effective filtration
pressure gradient across the glomerular capillaries
(DPF):(MAP-A)¼DPF¼ SIUNaV. This equation indicates
that patients with high sodium sensitivity, i.e., the cardio-
vascular burden, are predisposed toward glomerular hyper-
tension, resulting in proteinuria. ARB can achieve a lower
steady sodium balance, and the diuretic effect can be
enhanced by sodium deprivation.3 These findings can
explain why ARBs prevented the cardiovascular events
more effectively, under a lower sodium diet in post hoc
analysis of the RENAAL and IDNT studies;4 that is, the effect
of ARBs on sodium dynamics is the key to sever cardio-
renal connection. Therefore, we eagerly await the OSCAR
subanalysis in which subjects are examined according to the
presence of proteinuria, a clinical clue to high sodium
sensitivity.
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The Authors Reply:We read with interest the letter by Fukuda
and Miura,1 in response to our article. As they commented, the
degree of sodium intake is known to significantly affect the
effectiveness of angiotensin II receptor blockers (ARBs) in
patients with chronic kidney disease. However, in the OSCAR
study, we did not monitor urinary sodium levels and therefore,
the role of salt sensitivity in the OSCAR study is unclear.
Furthermore, it is unknown whether the elderly patients enrolled
in the OSCAR study exhibited glomerular hypertension or not.
Unfortunately, measurement of urinary protein or albumin was
not performed in the OSCAR study. However, 680 patients of
1164 enrolled patients had urinary protein test by dipstick
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Figure 1 | Kaplan–Meier curves. For primary composite end points during the follow-up period in patients (a) with and (b) without
proteinuria. ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio.
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analysis at baseline. According to the request, we present the
subgroup analysis data according to the presence or absence of
proteinuria at baseline (Figure 1). In patients with urinary
protein þ 1 or greater, more primary events (a composite of
cardiovascular events and non-cardiovascular death) occurred in
the high-dose ARB group than in the ARB þ calcium channel
blocker (CCB) group (15 vs 5 events, hazard ratio (HR), 3.31,
95% confidence interval (CI) 1.12–9.8; P¼ 0.0254). On the other
hand, in patients with urinary protein – or ±, the incidence of
primary events was similar between the two treatments
(HR¼ 1.13, 95% CI 0.61–2.09; P¼ 0.7034). Thus, our sub-
analysis suggests that ARBþCCB combination, compared to
high-dose ARB, conferred greater benefit in prevention of
cardiovascular events in patients with proteinuria, being
consistent with the findings2 on patients with estimated
glomerular filtration rate of o60ml/min per 1.73m2. The
superiority of ARBþCCB combination might be at least in part
attributed to the potential improvement of renal blood flow
through arterial vasodilation, because the elderly patients are
characterized by significant vascular stiffness. However, further
clinical study is required to define our proposal, as the number
of patients in the OSCAR study is limited.
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Why are complements activated in
anti-neutrophil cytoplasmic
antibody–associated vasculitis?
To the Editor: We read with great interest the recent contri-
bution by Gou et al.1 They investigated the circulating
complement activation profiles of patients with anti-
neutrophil cytoplasmic antibody–associated vasculitis (AAV)
and found that complement activation markers such as
plasma levels of C3a, C5a, soluble C5b-9, and Bb were
significantly higher in active stage than during remission
of AAV.1 However, they did not explicate the possible
mechanisms. We would like to suggest a possible patho-
mechanism of complement activation in AAV.
Vachino et al.2 previously reported that, in most cancer
patients who were treated with high-dose recombinant
interleukin-2 (IL-2), pretreatment plasma levels of C3a, Ba, Bb,
and SC5b-9 were comparable with those measured in normal
donor plasma. However, C3a levels had increased 15.6-fold at the
end of the treatment course. Bb and SC5b-9 levels had also
increased 5.0-fold.2 Furthermore, Arranz et al.3 found that the
concentrations of serum-soluble interleukin-2 receptor (sIL-2R)
were significantly higher in AAV during the active phase than
during the inactive phase (Po0.05), and serum sIL-2R levels
were significantly increased in these patients than a group of
healthy subjects (Po0.05). In addition, serum sIL-2R levels
correlated with serum levels of C-reactive protein (Po0.05).3
Therefore, there is a possibility that complement systems
could be activated by IL-2, which might be increased at the
active stage of AAV. However, further studies are necessary
to elucidate the exact molecular signaling pathway of IL-2
influence on the complement system and to evaluate why
AAV generally does not show hypocomplementemia or
complement deposition in the kidney.
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The Authors Reply: We appreciate the interest of Kim et al.1
in our study on complement in ANCA-associated vasculitis
(AAV).2 We agree that further exploration of the mechanisms
of complement activation in AAV would be of great interest.
The possible mechanisms of complement activation in AAV
have been previously studied by Xiao et al.3 Incubating normal
human neutrophils, primed by tumor necrosis factor-a, with
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